366 A randomized double-blind placebo-controlled phase III study evaluating perioperative toripalimab combined with platinum-based doublet chemotherapy in resectable stage III NSCLC
Wenxiang Wang(Peking University), Tao Xu(Peking University), Xiaosheng Hang(Wuxi Fourth People's Hospital), Wentao Fang(Shanghai Jiao Tong University), Wengang Zhang(Chinese PLA General Hospital), Aihong Zhong(Peking University), Minhua Ye(Jiangxi University of Water Resources and Electric Power), Ming Zhou(Central South University), Haohui Fang(Anhui Provincial Hospital), Qixun Chen(Zhejiang Cancer Hospital), Xiaoyan Kang(Qilu Hospital of Shandong University), Nong Yang(Central South University), Guowu Wu(Meizhou City People's Hospital), Jie Jiang(University of Copenhagen), Lin Wu(Materials Systems (United States)), Wei Zhang(Nanchang University), Yunpeng Liu(Wenzhou Medical University), Yu Zhang(Nanjing Chest Hospital), Jun Chen(Fourth People's Hospital of Taiyuan), Xun Zhang(Harbin University of Science and Technology), Jichun Liu(Nanchang University), Ying Tian(NARI Group (China)), Shanqing Li(Peking Union Medical College Hospital), Guohua Yu(Weifang People's Hospital), Yunchao Huang(North China University of Water Resources and Electric Power), Wenqun Xing(Zhengzhou University), Xingya Li(Zhengzhou University), Lijie Tan(Fudan University), Liwei Zhang(Xinjiang Medical University), Shun Lü(Shanghai Jiao Tong University)
Cited by 2
Related Papers
Food, nutrition, physical activity, and the prevention of cancer: a global perspective
|Choice Reviews Online|2008|5.4k
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
|Nature Medicine|2013|3k
Osimertinib in Resected <i>EGFR</i> -Mutated Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2020|1.7k